



**NEW YORK CITY DEPARTMENT OF
HEALTH AND MENTAL HYGIENE**

Ashwin Vasan, MD, PhD

Commissioner

May 20, 2022

Dear Colleague,

The Centers for Disease Control and Prevention (CDC) has updated its [clinical considerations](#) to recommend that **children ages 5 to 11 years should receive a single 10-mcg booster dose of the Pfizer COVID-19 vaccine at least 5 months after completing the primary series.**^a This update follows a recommendation of the Advisory Committee on Immunization Practices and revisions to the U.S. Food and Drug Administration (FDA)'s Emergency Use Authorization. FDA's fact sheets for Pfizer vaccine for children ages 5 to 11 years for [recipients and caregivers](#) and [health care providers](#) have been revised.


In addition, the CDC strengthened its COVID-19 vaccination guidance to recommend that **everyone ages 50 years and older who received any COVID-19 booster dose and everyone ages 12 years and older who are moderately or severely immunocompromised should receive a second booster dose using an mRNA COVID-19 vaccine** to help restore protection that may wane over time. Previously, these populations were recommended to consider a second booster dose based on their individual circumstances. This strengthened recommendation is in response to a steep and substantial increase in hospitalizations for older Americans over the past few weeks.

Ongoing [safety monitoring data](#) in children ages 5 to 11 years continue to demonstrate the COVID-19 vaccine is safe in this age group and that [the benefits of COVID-19 vaccines for children continue to outweigh the risks](#). A study of children ages 5 to 11 years also supported the safety and immunogenicity of a booster dose after a median follow-up time of 1.3 months. During the Omicron-predominant period, two-dose [vaccine effectiveness](#) against infection declined quickly in both children ages 5 to 11 years and adolescents ages 12 to 15 years. A booster dose in adolescents significantly improved vaccine effectiveness against infection and emergency department and urgent care visits; there was insufficient data to assess the impact of a booster dose for adolescents against severe disease. [Evidence among adults](#) also shows that a booster dose improves protection across all outcomes studied.

The CDC continues to recommend that all unvaccinated children ages 5 years and older receive a COVID-19 vaccine primary series. In New York City, only 47% of children in this age group have completed the primary series. Children ages 5 to 11 years are at risk for severe illness from COVID-19, with more than 4.8 million reported cases and more than 15,000 hospitalizations, to date. In 2020, COVID-19 was a leading cause of death in children ages 5 to 11 years. Children who have received a COVID-19 vaccine primary series have [significantly better outcomes](#) than children who are unvaccinated, particularly against severe illness, and this pattern continued during the Omicron-predominant period.

Thank you for your commitment to promoting and protecting the health of New Yorkers.

Sincerely,

A handwritten signature in black ink that reads "Jane R. Zucker". The signature is written in a cursive, flowing style.

Jane R. Zucker, MD, MSc
Assistant Commissioner
Bureau of Immunization

- a. The Pfizer COVID-19 vaccine primary series for children ages 5 to 11 years consists of two doses (for children who are not moderately or severely immunocompromised) or three doses (for children who are moderately or severely immunocompromised).